Study to Gather Information About the Proper Dosing of the Oral FXIa

Status Completed

Clinical Trial Summary

The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works in patients with irregular heartbeat (atrial fibrillation) that can lead to blood clots, stroke and other heart-related complications. In addition researchers want to compare the safety of the study drug to apixaban, a non-vitamin K oral anticoagulant (NOAC) in patients with atrial fibrillation. This study is also done to learn how the drug in this study moves into, through and out of the body. BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor. Apixaban, works by reducing the production of blood clotting factors in our body and thins the blood and is a so called non-vitamin K oral anticoagulant (NOAC). Thinning the blood can prevent you from blood clots which can cause a stroke.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04218266
Study type	Interventional
Source	Bayer
Contact
Status	Completed
Phase	Phase 2
Start date	January 30, 2020
Completion date	October 8, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02630914` - Medical and Surgical Hybrid Treatment of Atrial Fibrillation.	N/A
Completed	`NCT05410379` - Antral Lesions Characterization of a New Cryoballoon Ablation System in Terms of Local Impedance Drop
Enrolling by invitation	`NCT05407415` - KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial Fibrillation	N/A
Completed	`NCT04025710` - Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)	N/A
Completed	`NCT01119274` - EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon	Phase 4
Recruiting	`NCT03428048` - Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.
Recruiting	`NCT04298723` - Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.	N/A
Active, not recruiting	`NCT03732794` - AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment	N/A
Active, not recruiting	`NCT04755283` - Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation	Phase 2
Completed	`NCT04095559` - Characterization of Left Atrial Substrate by Comparison of Bipolar Voltage Maps With Standard Focal 4.5 mm Tip Electrode, 1 mm Ring Electrode, and Microelectrode Catheters Using InTEllaMap Orion and IntellaNav MIFI O
Recruiting	`NCT05712200` - Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)	Phase 3
Recruiting	`NCT05955365` - Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation	Phase 4
Recruiting	`NCT05294445` - From the Emergency Department Directly to Ablation of Atrial Fibrillation Study	N/A
Completed	`NCT02513316` - Clinical Relevance of Microbleeds In Stroke	N/A
Completed	`NCT04809922` - Accuracy of Cardiac Wearables Devices to Detect Atrial Fibrillation